| Overview |
| bsm-90149R |
| AGL Recombinant Antbody Kit (KD-Validated) |
| WB, FCM, IC |
| Knockdown Validated |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| A synthesized peptide derived from human AGL |
| 60-90/1532 |
| Monoclonal |
| IgG |
| Lot dependent |
| Affinity Purified |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| -20 °C |
| Target |
| 178 |
| P35573 |
| AGL; Amylo-Alpha-1 6-Glucosidase 4-Alpha-Glucanotransferase; GDE; Glycogen Debranching Enzyme; Amylo-1 6-Glucosidase 4-Alpha-Glucanotransferase; Glycogen Debrancher; Amylo-Alpha-1 6-Glucosidase 4-Alpha-Glucanotransferaseprovided; Glycogen Storage Disease Type III; Glycogen Debranching Protein |
| Cell Line: Hela Knockdown technology: shRNA Knockdown |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IC |
1:1000 |
Powered by Bioz